Keryx Biopharmaceuticals Inc (KERX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012281
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric (ferric citrate coordination complex). The company has subsidiaries and offices in Israel, the US, and the UK. Keryx is headquartered in New York, the US.

Keryx Biopharmaceuticals Inc (KERX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 11
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 12
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 16
Keryx BioPharma Completes Underwritten Public Offering Of US$33 Million 18
Debt Offering 20
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Acquisition 21
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc – Key Competitors 22
Keryx Biopharmaceuticals Inc – Key Employees 23
Keryx Biopharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2017: Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results 25
Jul 27, 2017: Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance 27
May 04, 2017: Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results 29
Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 31
Nov 09, 2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update 33
Aug 01, 2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results 35
Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results 36
Feb 25, 2016: Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results 38
Corporate Communications 40
Sep 13, 2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors 40
Jun 21, 2016: Keryx Biopharmaceuticals Appoints Two New Board Members 41
Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 11
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 12
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 16
Keryx BioPharma Completes Underwritten Public Offering Of US$33 Million 18
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc, Key Competitors 22
Keryx Biopharmaceuticals Inc, Key Employees 23
Keryx Biopharmaceuticals Inc, Subsidiaries 24

★海外企業調査レポート[Keryx Biopharmaceuticals Inc (KERX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Luminex Corp (LMNX):企業の財務・戦略的SWOT分析
    Luminex Corp (LMNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Allergy Therapeutics Plc (AGY):製薬・医療:M&Aディール及び事業提携情報
    Summary Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alter …
  • Banner Corp:企業の戦略・SWOT・財務情報
    Banner Corp - Strategy, SWOT and Corporate Finance Report Summary Banner Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • HL Global Enterprises Limited:企業の戦略・SWOT・財務情報
    HL Global Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary HL Global Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Oceanteam ASA (OTS):企業の財務・戦略的SWOT分析
    Oceanteam ASA (OTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Bank Of Ireland (Uk) Plc:企業の戦略・SWOT・財務分析
    Bank Of Ireland (Uk) Plc - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ireland (Uk) Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • PharmaEngine Inc (4162):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaEngine Inc (PharmaEngine) is a biopharmaceutical company that discovers and develops cancer treatment drugs and related medicinal products. The company develops drugs for the treatment of cancer and Asian prevalent diseases. Its products include Onivyde a liposome encapsulation of irin …
  • Exicure Inc-製薬・医療分野:企業M&A・提携分析
    Summary Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC, is a biotechnology company that develops and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid (SNA) constructs. Its technology portfolio includes SNA gene regulation platform and …
  • Black & Veatch Corp:企業の戦略的SWOT分析
    Black & Veatch Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Microvision Inc (MVIS):企業の財務・戦略的SWOT分析
    Summary Microvision Inc (Microvision) is a technology company that provides scanning technology solutions. The company offers technology solutions including PicoP scanning technology, an ultra-miniature laser projection and imaging solutions based on the laser beam scanning methodology. It also prov …
  • TransUnion LLC:企業のM&A・事業提携・投資動向
    TransUnion LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TransUnion LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Teva Pharmaceuticals USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Teva Pharmaceuticals USA Inc (Teva Pharmaceuticals), formerly Lemmon Pharmacal Company, a subsidiary of Teva Pharmaceutical Industries Ltd, is a developer and manufacturer of pharmaceutical ingredients. The company’s products include antiulcer agents and acid suppressants, antiviral capsules …
  • Bioplus Life Sciences Private Limited:戦略・SWOT・企業財務分析
    Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report Summary Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Fresenius SE & Co KGaA (FRE)-製薬・医療分野:企業M&A・提携分析
    Summary Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes mach …
  • Citius Pharmaceuticals Inc (CTXR):企業の財務・戦略的SWOT分析
    Summary Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Min …
  • PTT Public Company Limited:戦略・SWOT・企業財務分析
    PTT Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary PTT Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Helm AG:企業の戦略・SWOT・財務情報
    Helm AG - Strategy, SWOT and Corporate Finance Report Summary Helm AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Powszechny Zaklad Ubezpieczen Group:企業の戦略・SWOT・財務情報
    Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report Summary Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Ingram Micro Inc.:企業の戦略的SWOT分析
    Ingram Micro Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Kohl’s Corp (KSS):企業の財務・戦略的SWOT分析
    Kohl's Corp (KSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆